Sonoma Pharmaceuticals, Inc. (SNOA): Price and Financial Metrics
SNOA Price/Volume Stats
| Current price | $0.77 | 52-week high | $3.34 |
| Prev. close | $0.78 | 52-week low | $0.72 |
| Day low | $0.72 | Volume | 74,400 |
| Day high | $0.78 | Avg. volume | 855,587 |
| 50-day MA | $0.94 | Dividend yield | N/A |
| 200-day MA | $1.10 | Market Cap | 3.97M |
SNOA Stock Price Chart Interactive Chart >
SNOA Stock Summary
- SONOMA PHARMACEUTICALS INC's market capitalization of $4,011,360 is ahead of merely 2.2% of US-listed equities.
- With a year-over-year growth in debt of -31.2%, SONOMA PHARMACEUTICALS INC's debt growth rate surpasses just 10.31% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SNOA comes in at -67.41% -- higher than that of just 8.47% of stocks in our set.
- Stocks that are quantitatively similar to SNOA, based on their financial statements, market capitalization, and price volatility, are ADSE, SPWR, TREE, RMTI, and EVER.
- SNOA's SEC filings can be seen here. And to visit SONOMA PHARMACEUTICALS INC's official web site, go to www.sonomapharma.com.
SNOA Valuation Summary
- In comparison to the median Healthcare stock, SNOA's price/earnings ratio is 102.62% lower, now standing at -0.7.
- SNOA's price/earnings ratio has moved up 3.4 over the prior 203 months.
Below are key valuation metrics over time for SNOA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SNOA | 2023-09-22 | 0.3 | 0.6 | -0.7 | -0.2 |
| SNOA | 2023-09-21 | 0.3 | 0.5 | -0.7 | -0.2 |
| SNOA | 2023-09-20 | 0.3 | 0.5 | -0.7 | -0.2 |
| SNOA | 2023-09-19 | 0.4 | 0.6 | -0.8 | -0.3 |
| SNOA | 2023-09-18 | 0.4 | 0.6 | -0.8 | -0.3 |
| SNOA | 2023-09-15 | 0.4 | 0.7 | -0.9 | -0.3 |
SNOA Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at -72.64%.
- Its 3 year net income to common stockholders growth rate is now at 56.89%.
- Its year over year cash and equivalents growth rate is now at 75.26%.
The table below shows SNOA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 12.556 | -5.106 | -6.787 |
| 2022-09-30 | 12.514 | -5.084 | -5.792 |
| 2022-06-30 | 12.927 | -4.558 | -4.875 |
| 2022-03-31 | 12.628 | -4.248 | -5.086 |
| 2021-12-31 | 12.487 | -4.329 | -5.802 |
| 2021-09-30 | 14.521 | -3.257 | -5.508 |
SNOA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SNOA has a Quality Grade of D, ranking ahead of 19.4% of graded US stocks.
- SNOA's asset turnover comes in at 1.011 -- ranking 24th of 682 Pharmaceutical Products stocks.
- AGLE, REGN, and NAVB are the stocks whose asset turnover ratios are most correlated with SNOA.
The table below shows SNOA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.011 | 0.348 | -0.457 |
| 2021-03-31 | 1.064 | 0.352 | -0.307 |
| 2020-12-31 | 1.210 | 0.393 | -0.153 |
| 2020-09-30 | 1.226 | 0.405 | -0.202 |
| 2020-06-30 | 1.214 | 0.411 | -0.353 |
| 2020-06-30 | 1.305 | 0.416 | -0.272 |
Sonoma Pharmaceuticals, Inc. (SNOA) Company Bio
Sonoma Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. Sonoma Pharmaceuticals serves customers worldwide.
Latest SNOA News From Around the Web
Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has received the National Eczema |
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2023. |
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory BoardSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard |
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial ResultsSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2023 and the fourth quarter ended March 31, 2023. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time for a final look at the biggest pre-market stock movers this week as we check out what's happening on Friday morning! |
SNOA Price Returns
| 1-mo | -16.30% |
| 3-mo | N/A |
| 6-mo | -18.35% |
| 1-year | -63.85% |
| 3-year | -90.78% |
| 5-year | -93.97% |
| YTD | -31.25% |
| 2022 | -75.44% |
| 2021 | -37.19% |
| 2020 | 66.51% |
| 2019 | -31.77% |
| 2018 | -86.97% |
Continue Researching SNOA
Want to see what other sources are saying about Sonoma Pharmaceuticals Inc's financials and stock price? Try the links below:Sonoma Pharmaceuticals Inc (SNOA) Stock Price | Nasdaq
Sonoma Pharmaceuticals Inc (SNOA) Stock Quote, History and News - Yahoo Finance
Sonoma Pharmaceuticals Inc (SNOA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...